Company Profile

Our business focus is on the discovery and development of drugs that modulate mitochondrial function in cancer, diabetes, cardiovascular diseases and neurodegenerative diseases.

We are building on an existing drug pipeline which consists of drugs which combine the actions of apoptosis inducers and angiogenesis inhibitors for use in the treatment of a wide range of solid and blood-borne cancers.

We are the only company in the World with a unique range of High Throughput Screening (HTS) assays and other contract research services for the measurement of mitochondrial function, and we can provide you with a competitive edge.

We are based at BioCity Nottingham, a state-of-the-art bioincubator in the heart of the city of Nottingham, England, U.K.

Our latest research published in the British Journal of Cancer in 2011 shows that Tricyclic Antidepressants can protect against colorectal cancer and glioma (a form of brain cancer). This research supports our previous work which demonstrated that a tricyclic antidepressant (chlorimipramine) can inhibit mitochondrial function, and induce apoptotic cell death in human glioma cells, whilst sparing normal human brain cells.

Other work by us has also shown that molecules such as capsaicin (a molecule in the vanilloid class of drugs) which brings about the burning sensation in the mouth in a curry and tetrahydrocannabinol (THC, a molecule in the cannabinoid class of drugs) can also act as mitochondrial ligands and bring about apoptosis in cancer cells.

The above studies all support the hypothesis of our founder Dr. Timothy E. Bates, that "the mitochondria in cancer cells represent a fundamental 'Achilles Heel', and are an exciting new drug target."